Viral vectors are increasingly being used to develop therapeutics and vaccines for which genetic information forms the active ingredient. This method utilises the efficiency with which viruses deliver genetic information to cells they infect to produce an effective delivery system.
Incorporation of therapeutic or antigenic genetic information into inactive viral capsids therefore gives a highly effective means of getting such therapies to their target. Understandably, it is key to ensure proper insertion of the active genetic information into the vectoring capsids. It is also very important to optimise the stability of viral vectors, ensuring their integrity (and the retention of their cargo) during processing and storage.
In this webinar, the use of multi-detection SEC (MALS) as a sensitive, label-free means of accurately quantifying the success of viral capsid-loading procedures will be discussed – essential information to anyone seeking to optimise the loading process and monitor cargo-retention further along the workflow. The use of the same method to monitor capsid aggregation will also be elaborated on, as will the use of DSC as a tool for optimising and proving capsid/formulation stability.
So if you are interested in understanding the tools at your disposal for optimising the efficacy and stability of gene therapy products, please do register and join this session, which will include a Q+A session to answer any questions you may have.
- August 25 2021 - August 25 2021
11:30 - 12:30
India Time [Asia]
- Webinar - Live
Size Exclusion Chromatography (SEC)
Dr Michael Caves, Malvern Panalytical's Pharma segment manager
Dr Michael Caves has spent 20 years working in various academic and commercial life science settings. He has published scientific papers on biotherapeutic characterisation and formulation, and has applied this knowledge during various roles within the pharmaceutical and diagnostics industries. Having helped build the formulation development service at SGS Life Sciences, Michael joined Malvern Panalytical in 2013 in order to support customers around the world. Michael is currently based in Chennai, India, from where he focuses on helping customers across Asia’s pharmaceutical industry.
Who should attend?
• Scientists working on development of viral vector gene therapies and viral vaccines.
• Anyone who wants to expand their analytical characterization knowledge
• Anyone who wants to grow in their application knowledge about SEC and DSC characterization methods
How long is this webinar?
30 minutes is the intended speaker time with additional time for addressing queries.
Join our free MasterClass series on gene therapy and viral vectors analysis
- Webinar 1: Comprehensive viral vector characterization: The value of rapid label-free biophysical techniques. More info
- Webinar 2: Quantifying rAAV and other viral vector quality attributes with Multi-angle DLS and nanoparticle tracking analysis. More info
- Webinar 3: Optimising loading time and stability of Virally Vectored therapies and vaccines using SEC and DSC